Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
26/05/2026 12:38
BRIEF-Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile May 26 (Reuters) - Biohaven Ltd BHVN.N:
BIOHAVEN REPORTS NEW CLINICAL DATA IN EPILEPSY WITH OPAKALIM, A SELECTIVE KV7.2/7.3 ACTIVATOR, HIGHLIGHTING SEIZURE CONTROL AND MARKEDLY DIFFERENTIATED TOLERABILITY PROFILE
BIOHAVEN LTD - OPAKALIM PROLONGS MEDIAN TIME TO SECOND SEIZURE TO 141 DAYS VERSUS. 47 DAYS FOR PLACEBO
BIOHAVEN LTD - ON TRACK FOR TOP-LINE PHASE 2/3 RESULTS IN REFRACTORY FOCAL EPILEPSY IN 2H 2026
Source text: ID:nPn95Tlwda
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing